Gaël Chételat|Renaud La Joie|Nicolas Villain|Audrey Perrotin|Vincent de La Sayette|Francis Eustache|Rik Vandenberghe
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease
Centre Hospitalier Universitaire de Caen|Université de Caen Normandie|Inserm|École Pratique des Hautes Études|Centre Hospitalier Universitaire de Caen|Université de Caen Normandie|Inserm|École Pratique des Hautes Études|Centre Hospitalier Universitaire de Caen|Université de Caen Normandie|Inserm|École Pratique des Hautes Études|Centre Hospitalier Universitaire de Caen|Université de Caen Normandie|Inserm|École Pratique des Hautes Études|Centre Hospitalier Universitaire de Caen|Université de Caen Normandie|École Pratique des Hautes Études|Inserm|Centre Hospitalier Universitaire de Caen|Université de Caen Normandie|Inserm|École Pratique des Hautes Études|KU Leuven
recent developments pet amyloid ligands made possible visualize presence deposition brain living participants assess consequences especially individuals objective sign cognitive deficits present review focus amyloid imaging cognitively normal elderly asymptomatic atrisk populations individuals subjective cognitive decline cover prevalence amyloidpositive cases amongst cognitively normal elderly influence risk factors ad relationships cognition atrophy prognosis longitudinal amyloid imaging ethical aspects related amyloid imaging cognitively normal individuals almost ten years research led consensual relatively consistent findings cognitively normal elderly deposition brain prevalence amyloidpositive cases increases atrisk populations prognosis individuals worse deposition significant increase deposition time detectable cognitively normal elderly inconsistent findings still debate include relationship deposition cognition brain volume sequence causetoeffect relations different ad biomarkers individual outcome associated amyloid positive versus negative scan preclinical amyloid imaging also raises important ethical issues amyloid imaging definitely useful understand role early stages define atrisk populations research clinical trial assess effects antiamyloid treatments ready yet translate research results clinical practice policy researches needed determine information disclose individual amyloid imaging scan way disclosing information impact individuals society